Get access

Lower-dose thalidomide therapy effectively treats cutaneous lupus erythematosus but is limited by neuropathic toxicity

Authors


  • Conflicts of interest: AAQ serves as a consultant to Novartis Corporation, East Hanover, NJ, USA and Janssen Pharmaceuticals, Inc., Titusville, NJ, USA

Abrar A. Qureshi, md, mph
Department of Dermatology
Alumnae HallBrigham and Women's Hospital75 Francis StreetBostonMA 02115
USA
E-mail: abrar.qureshi@channing.harvard.edu

No abstract is available for this article.

Ancillary